GlassScriptPhysician profile
Ruth Neal
NPI 1396414827
$4,455.64
in general payments reported to CMS, 2019-2025
34 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.39 · 2022: $1,079 · 2023: $149 · 2024: $1,155 · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,325.64 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $729.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $653.87 | 2022-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $473.32 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $319.33 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $315.01 | 2022-2023 | |
| Lilly USA, LLC | $284.47 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Ascensia Diabetes Care US INC. | $215.39 | 2022 | |
| Radius Health, INC. | $206.25 | 2025 | Tymlos |
| Corcept Therapeutics | $192.15 | 2022-2025 | Korlym |
| Inspire Medical Systems, INC. | $129.38 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.98 | 2024-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $92.51 | 2024 | Signifor Lar, Isturisa |
| Grt US Holding, INC. | $89.48 | 2022 | |
| Abbvie INC. | $79.04 | 2022-2025 | |
| Cequr Corporation | $63.49 | 2024-2025 | Cequr Simplicity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $57.52 | 2025 | Twiist |
| Mannkind Corporation | $48.16 | 2022 | |
| Convatec INC. | $37.06 | 2025 | |
| Amgen INC. | $36.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $34.84 | 2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $33.74 | 2025 | Unithroid |
| Globus Medical, INC. | $30.88 | 2025 | Senza |
| Beta Bionics, INC. | $28.12 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Coloplast Corp | $24.89 | 2024 | |
| Kyowa Kirin, INC. | $22.81 | 2025 | |
| Pfizer INC. | $22.23 | 2024 | |
| Neurocrine Biosciences, INC. | $20.80 | 2025 | |
| Teleflex LLC | $18.80 | 2025 | Barrigel |
| Merck Sharp & Dohme LLC | $17.62 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $16.31 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $15.39 | 2025 | Gemtesa |
| Exact Sciences Corporation | $14.53 | 2024 | Cologuard Collection Kit |
| Soleno Therapeutics, INC. | $14.39 | 2025 | Vykat Xr |
| Orthofix Medical, INC. | $11.72 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Neal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.